Oppenheimer raised the firm’s price target on Kymera Therapeutics (KYMR) to $63 from $53 and keeps an Outperform rating on the shares as STAT-6 targeting KT-621 moves into Phase 2 studies in Q4 2025. The firm continues to anticipate results from Kymera’s ongoing Phase 1b BroADen study of ‘621 in AD patients during Q4 as well. The anticipated clinical phase transition drives an increase in its estimated PoA to 33% from 25%, with this program being a key value driver to the Kymera story, in Oppenheimer’s view.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $68 from $53 at Truist
- Kymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright
- Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements
- Kymera Therapeutics to present on KT-621 at EADV Congress
- Kymera Therapeutics initiated with an Overweight at Barclays